CAJ | 학술논문

目的对比贝那普利及厄贝沙坦对慢性肾脏病患者蛋白尿产生的影响.方法将135例慢性肾脏病患者随机分为I、I、I I 3组,每组45例,分别实施贝那普利、厄贝沙坦以及两者联合疗法,对比治疗前后患者24 h尿蛋白定量、Scr、BUN、UA、K+其他改变情况.结果经治疗后,3组患者24 h尿蛋白定量与治疗前相比均出现不同幅度的降低,差异有统计学意义(P<0.05),治疗后I I组降低幅度最大,大于I、I两组(P<0.05),存在统计学意义.3组之间比较其他各项指标与治疗前相比无明显差异,P>0.05.结论厄贝沙坦与贝那普利均能够有效降低慢性肾脏病的蛋白尿水平,并且两者合用效果更加显著.
목적대비패나보리급액패사탄대만성신장병환자단백뇨산생적영향.방법장135례만성신장병환자수궤분위I、I、I I 3조,매조45례,분별실시패나보리、액패사탄이급량자연합요법,대비치료전후환자24 h뇨단백정량、Scr、BUN、UA、K+기타개변정황.결과경치료후,3조환자24 h뇨단백정량여치료전상비균출현불동폭도적강저,차이유통계학의의(P<0.05),치료후I I조강저폭도최대,대우I、I량조(P<0.05),존재통계학의의.3조지간비교기타각항지표여치료전상비무명현차이,P>0.05.결론액패사탄여패나보리균능구유효강저만성신장병적단백뇨수평,병차량자합용효과경가현저.
Objective To explorer the value of Benazepril Hydrochloride and Irbesartan in chronic kidney disease patients with proteinuria. Methods 135 chronic kidney disease patients were divided into 3 groups in random,Group I were treated with Benazepril Hydrochloride,Group II were treated with Irbesartan,while Group III were treated with Benazepril Hydrochloride plus Irbesartan for 12 weeks. Comparative analysis of treatment of patients before and after 24 h urine protein and other various index changes. Results After the treatment, three patients in group 24 h urine protein compared with before treatment showed varying amplitude decreases, significant difference(P<0.05), group III decreased the amplitude maximum, was significantly higher than that of group I, II (P<0.05), there was statistical significant difference. Conclusion Two kinds of drugs were able to reduce patients with proteinuria levels, and the effect of the combination is more obvious.